Evidence map›Paper›PMID 37747506›Full record

ArticlePsychopharmacology2024

Inhibition of fatty acid binding protein-5 in the basolateral amygdala induces anxiolytic effects and accelerates fear memory extinction.

Matthew J Jones, Taygun C Uzuneser, Timothy Clement, Hehe Wang, Iwao Ojima, Walter J Rushlow, Steven R Laviolette

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Matthew J JonesDepartment of Neuroscience, Schulich School of Medicine and Dentistry, University of Western Ontario, 1151 Richmond St, London, ON, Canada.ORCID http://orcid.org/0009-0004-0181-4468
Taygun C UzuneserDepartment of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, University of Western Ontario, 1151 Richmond St, London, ON, Canada.
Timothy ClementInstitute of Chemical Biology and Drug Discoveries, Stony Brook University, 100 Nicolls Road, Stony Brook, NY, USA.
Hehe WangInstitute of Chemical Biology and Drug Discoveries, Stony Brook University, 100 Nicolls Road, Stony Brook, NY, USA.
Iwao OjimaInstitute of Chemical Biology and Drug Discoveries, Stony Brook University, 100 Nicolls Road, Stony Brook, NY, USA.
Walter J RushlowDepartment of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, University of Western Ontario, 1151 Richmond St, London, ON, Canada.
Steven R LavioletteDepartment of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, University of Western Ontario, 1151 Richmond St, London, ON, Canada. steven.laviolette@schulich.uwo.ca.
Western University · CAStony Brook University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleThe endocannabinoid (eCB) system critically controls anxiety and fear-related behaviours. Anandamide (AEA), a prominent eCB ligand, is a hydrophobic lipid that requires chaperone proteins such as Fatty Acid Binding Proteins (FABPs) for intracellular transport. Intracellular AEA transport is necessary for degradation, so blocking FABP activity increases AEA neurotransmission.

objectiveTo investigate the effects of a novel FABP5 inhibitor (SBFI-103) in the basolateral amygdala (BLA) on anxiety and fear memory.

methodsWe infused SBFI-103 (0.5 μg-5 μg) to the BLA of adult male Sprague Dawley rats and ran various anxiety and fear memory behavioural assays, neurophysiological recordings, and localized molecular signaling analyses. We also co-infused SBFI-103 with the AEA inhibitor, LEI-401 (3 μg and 10 μg) to investigate the potential role of AEA in these phenomena.

resultsAcute intra-BLA administration of SBFI-103 produced strong anxiolytic effects across multiple behavioural tests. Furthermore, animals exhibited acute and long-term accelerated associative fear memory extinction following intra-BLA FABP5 inhibition. In addition, BLA FABP5 inhibition induced strong modulatory effects on putative PFC pyramidal neurons along with significantly increased gamma oscillation power. Finally, we observed local BLA changes in the phosphorylation activity of various anxiety- and fear memory-related molecular biomarkers in the PI3K/Akt and MAPK/Erk signaling pathways. At all three levels of analyses, we found the functional effects of SBFI-103 depend on availability of the AEA ligand.

conclusionsThese findings demonstrate a novel intra-BLA FABP5 signaling mechanism regulating anxiety and fear memory behaviours, neuronal activity states, local anxiety-related molecular pathways, and functional AEA modulation.

Indexed as

Anti-Anxiety AgentsBasolateral Nuclear ComplexAmygdalaAnimalsBenzofuransEthers, CyclicExtinction, PsychologicalEye ProteinsFatty Acid-Binding ProteinsFearLigandsMaleNerve Tissue ProteinsPhosphatidylinositol 3-KinasesRatsRats, Sprague-DawleyAnti-Anxiety AgentsBenzofuransEthers, CyclicEye ProteinsFabp5 protein, ratFatty Acid-Binding ProteinsLigandsNerve Tissue ProteinsPhosphatidylinositol 3-Kinasessodium-binding benzofuran isophthalateAnandamideAnxietyBasolateral amygdalaBehavioural pharmacologyEndocannabinoid systemFear memoryIn vivo electrophysiology

Identifiers

PMID37747506
OpenAlexW4387002616

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.